文献速递妇科

植物来源药物治疗子宫内膜异位症:临床前与临床研究综述

Plants as source of new therapies for endometriosis: a review of preclinical and clinical studies.
PubMed 文献 · Hum Reprod Update · 2021-01-01

本综述汇总了植物来源药物(草药提取物、特定植物源生物活性化合物、中草药)用于子宫内膜异位症的临床前与临床研究。特定化合物在实验模型中显示抑制活性,中草药可缩小病灶、缓解疼痛并降低术后复发率,但整体证据仍有限,需进一步研究。

要点

  • 植物源药物分为草药提取物、特定生物活性化合物和中草药三类。
  • 白藜芦醇、姜黄素等化合物在实验模型中显示抑制子宫内膜异位症的作用。
  • 中草药可缩小病灶、缓解慢性盆腔痛并降低术后复发率。

核心结论

  • 植物来源药物是有前景的候选,可能提高疗效并减少副作用,但现有证据仍有限。

研究设计与样本

  • 检索PubMed和Clinicaltrials.gov,纳入动物和人类研究,无发表时间限制。

主要发现

  • 草药提取物对子宫内膜细胞和病灶有抗增殖、抗炎、抗血管生成和抗氧化作用。
  • 特定化合物在实验模型中显示抑制活性,机制涉及雌激素受体α、环氧合酶-2、白细胞介素-1和-6等。
  • 中草药可缩小病灶、缓解慢性盆腔痛并降低术后复发率。

临床怎么用

  • 植物源药物可作为多模式治疗的一部分,旨在提高疗效并减少副作用。

局限性

  • 支持草药提取物用于子宫内膜异位症治疗的现有证据相当有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the disadvantages and limitations of current endometriosis therapy, there is a progressive increase in studies focusing on plant-derived agents as a natural treatment option with the intention of achieving high efficiency, avoiding adverse effects and preserving the chance for successful pregnancy. The heterogeneity of these studies in terms of evaluated agents, applied approaches and outcomes illustrates the need for an up-to-date summary and critical view on this rapidly growing field in endometriosis research. OBJECTIVE AND RATIONALE: This review provides a comprehensive overview of plant-derived agents and natural treatment strategies that are under preclinical or clinical investigation and critically evaluates their potential for future endometriosis therapy. SEARCH METHODS: An English language PubMed literature search was performed using variations of the terms 'endometriosis', 'natural therapy', 'herb/herbal', 'plant', 'flavonoid', 'polyphenol', 'phytochemical', 'bioactive', 'Kampo' and 'Chinese medicine'. It included both animal and human studies. Moreover, the Clinicaltrials.gov database was searched with the term 'endometriosis' for clinical trials on plant-derived agents. No restriction was set for the publication date. OUTCOMES: Natural therapies can be assigned to three categories: (i) herbal extracts, (ii) specific plant-derived bioactive compounds and (iii) Chinese herbal medicine (CHM). Agents of the first category have been shown to exert anti-proliferative, anti-inflammatory, anti-angiogenic and anti-oxidant effects on endometrial cells and endometriotic lesions. However, the existing evidence supporting their use in endometriosis therapy is quite limited. The most studied specific plant-derived bioactive compounds are resveratrol, epigallocatechin-3-gallate, curcumin, puerarin, ginsenosides, xanthohumol, 4-hydroxybenzyl alcohol, quercetin, apigenin, carnosic acid, rosmarinic acid, wogonin, baicalein, parthenolide, andrographolide and cannabinoids, with solid evidence about their inhibitory activity in experimental endometriosis models. Their mechanisms of action include pleiotropic effects on known signalling effectors: oestrogen receptor-α, cyclooxygenase-2, interleukin-1 and -6, tumour necrosis factor-α, intercellular adhesion molecule-1, vascular endothelial growth factor, nuclear factor-kappa B, matrix metalloproteinases as well as reactive oxygen species (ROS) and apoptosis-related proteins. Numerous studies suggest that treatment with CHM is a good choice for endometriosis management. Even under clinical conditions, this approach has already been shown to decrease the size of endometriotic lesions, alleviate chronic pelvic pain and reduce postoperative recurrence rates. WIDER IMPLICATIONS: The necessity to manage endometriosis as a chronic disease highlights the importance of identifying novel and affordable long-term safety therapeutics. For this purpose, natural plant-derived agents represent promising candidates. Many of these agents exhibit a pleiotropic action profile, which simultaneously inhibits fundamental processes in the pathogenesis of endometriosis, such as proliferation, inflammation, ROS formation and angiogenesis. Hence, their inclusion into multimodal treatment concepts may essentially contribute to increase the therapeutic efficiency and reduce the side effects of future endometriosis therapy.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Meresman GF, Götte M, Laschke MW, et al. Plants as source of new therapies for endometriosis: a review of preclinical and clinical studies. Hum Reprod Update. 2021. PMID: 33124671. doi:10.1093/humupd/dmaa039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。